Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
  • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
  • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/32—Nitrogen atom
  • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Definitions

• tenofovir alafenamide (isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine is tenofovir alafenamide.
• the hemifumarate form of tenofovir alafenamide is also referred to herein as tenofovir alafenamide hemifumarate.
• tenofovir alafenamide hemifumarate wherein the ratio of fumaric acid to tenofovir alafenamide is 0.5 ⁇ 0.1, or 0.5 ⁇ 0.05, or 0.5 ⁇ 0.01, or about 0.5.
• tenofovir alafenamide hemifumarate in a solid form.
• tenofovir alafenamide hemifumarate that has an X-ray powder diffraction (XRPD) pattern having 2theta values of
• tenofovir alafenamide hemifumarate wherein the XRPD pattern comprises 2theta values of 6.9 ⁇ 0.2°, 8.6 ⁇ 0.2°, 11.0 ⁇ 0.2°, 15.9 ⁇ 0.2°, and 20.2 ⁇ 0.2°.
• tenofovir alafenamide hemifumarate that has a differential scanning calorimetry (DSC) onset endotherm of 131 ⁇ 2 °C, or 131 ⁇ 1 °C.
• DSC differential scanning calorimetry
• a pharmaceutical composition comprising tenofovir alafenamide hemifumarate and a pharmaceutically acceptable excipient.
• the pharmaceutical composition further comprising an additional therapeutic agent.
• the additional therapeutic agent is selected from the group consisting of human immunodeficiency virus (HIV) protease inhibiting compounds, HIV
• nonnucleoside inhibitors of reverse transcriptase HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
• a method for treating a human immunodeficiency virus (HIV) infection comprising administering to a subject in need thereof a therapeutically effective amount of tenofovir alafenamide hemifumarate.
• a method for treating an HIV infection comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising tenofovir alafenamide hemifumarate.
• the method comprises administering to the subject one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV nonnucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
• additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV nonnucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
• a method for treating a hepatitis B virus (HBV) infection comprising administering to a subject in need thereof a therapeutically effective amount of tenofovir alafenamide hemifumarate.
• a method for treating an HBV infection comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition comprising tenofovir alafenamide hemifumarate.
• a method for preparing a pharmaceutical composition comprising combining tenofovir alafenamide hemifumarate and a pharmaceutically acceptable excipient to provide the pharmaceutical
• a method for preparing tenofovir alafenamide hemifumarate comprising subjecting a solution comprising a suitable solvent; fumaric acid; tenofovir alafenamide; and, optionally, one or more seeds of tenofovir alafenamide hemifumarate to conditions that provide for the crystallization of the fumaric acid and the tenofovir alafenamide.
• the solvent comprises acetonitrile.
• the solution is subjected to a temperature in the range of from about 0 °C to about 75 °C.
• tenofovir alafenamide hemifumarate for use in medical therapy.
• tenofovir alafenamide hemifumarate for the prophylactic or therapeutic treatment of an HIV infection.
• tenofovir alafenamide hemifumarate to treat an HIV infection.
• tenofovir alafenamide hemifumarate for use in treating an HIV infection is provided.
• tenofovir alafenamide hemifumarate for the prophylactic or therapeutic treatment of an HBV infection.
• tenofovir alafenamide hemifumarate to treat an HBV infection.
• tenofovir alafenamide hemifumarate for use in treating an HBV infection is provided.
• the methods of treating and the like comprise administration of multiple daily doses. In other embodiments, the methods of treating and the like comprise administration of a single daily dose.
• composition consisting essentially of tenofovir alafenamide hemifumarate.
• FIG. 1 shows the X-ray powder diffraction (XRPD) pattern of tenofovir alafenamide hemifumarate.
• FIG. 2 shows a graph of the DSC analysis of tenofovir alafenamide hemifumarate.
• FIG. 3 shows a graph of the thermogravimetric analysis (TGA) data for tenofovir alafenamide hemifumarate.
• FIG. 4 shows a graph of the dynamic vapor sorption (DVS) analysis of tenofovir alafenamide hemifumarate.
• a hemifumarate form of tenofovir alafenamide i.e., tenofovir alafenamide hemifumarate.
• This form may have a ratio (i.e., a stoichiometric ratio or mole ratio) of fumaric acid to tenofovir alafenamide of 0.5 ⁇ 0.1, 0.5 ⁇ 0.05, 0.5 ⁇ 0.01, or about 0.5, or the like.
• tenofovir alafenamide hemifumarate consists of fumaric acid and tenofovir alafenamide in a ratio of 0.5 ⁇ 0.1.
• tenofovir alafenamide hemifumarate consists essentially of fumaric acid and tenofovir alafenamide in a ratio of 0.5 ⁇ 0.1.
• tenofovir alafenamide hemifumarate has an XRPD pattern comprising 2theta values of 6.9 ⁇ 0.2°, 8.6 ⁇ 0.2°, 10.0 ⁇ 0.2°,
• tenofovir alafenamide hemifumarate has an XRPD pattern comprising at least four 2theta values selected from 6.9 ⁇ 0.2°, 8.6 ⁇ 0.2°, 10.0 ⁇ 0.2°, 1 1.0 ⁇ 0.2°, 12.2 ⁇ 0.2°, 15.9 ⁇ 0.2°, 16.3 ⁇ 0.2°, 20.2 ⁇ 0.2°, and 20.8 ⁇ 0.2°.
• tenofovir alafenamide hemifumarate has a DSC onset endotherm of 131 ⁇ 2 °C, or 131 ⁇ 1 °C.
• a tenofovir alafenamide hemifumarate composition comprises less than about 5% by weight of tenofovir alafenamide monofumarate.
• a tenofovir alafenamide hemifumarate composition comprises less than about 1% by weight of tenofovir alafenamide monofumarate.
• a tenofovir alafenamide hemifumarate composition comprises less than about 0.5% by weight of tenofovir alafenamide
• a tenofovir alafenamide hemifumarate composition comprises no detectable tenofovir alafenamide monofumarate.
• tenofovir alafenamide hemifumarate can be prepared using selective crystallization.
• An example of a scheme for this preparation method is as follows.
• the method can be carried out by subjecting a solution comprising: a) a suitable solvent; b) fumaric acid; c) tenofovir alafenamide; and, optionally, d) one or more seeds comprising tenofovir alafenamide hemifumarate, to conditions that provide for the crystallization of fumaric acid and tenofovir alafenamide.
• the starting solution can contain the single diastereomer of tenofovir alafenamide or a mixture of tenofovir alafenamide and one or more of its other diastereomers (e.g., GS-7339, as described in U.S. Patent No. 7,390,791).
• the selective crystallization can be carried out in any suitable solvent.
• the solvent comprises a protic solvent (e.g., water or isopropyl alcohol).
• the solvent comprises an aprotic organic solvent (e.g., acetone, acetonitrile (ACN), toluene, ethyl acetate, isopropyl acetate, heptane, tetrahydrofuran (THF), 2-methyl THF, methyl ethyl ketone, or methyl isobutyl ketone, or a mixture thereof).
• the solvent comprises ACN or a mixture of ACN and up to about 50% methylene chloride (by volume).
• crystallization also can be carried out at any suitable temperature, for example, a temperature in the range of from about 0 °C to about 70 °C. In one specific embodiment, the resolution is carried out at a temperature of about 0 °C.
• tenofovir alafenamide (isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine; described in, e.g., U.S. Patent No. 7,390,791), which is the major diastereomeric impurity in the active pharmaceutical ingredient.
• the hemifumarate form of tenofovir alafenamide can be more readily and easily separated from impurities than the monofumarate form.
• Other major advantages of tenofovir alafenamide hemifumarate over the monofumarate form include improved thermodynamic and chemical stability (including long-term storage stability), superior process reproducibility, superior drug product content uniformity, and a higher melting point.
• Tenofovir alafenamide hemifumarate is useful in the treatment and/or prophylaxis of one or more viral infections in man or animals, including infections caused by DNA viruses.
• RNA viruses herpesviruses (e.g., CMV, HSV 1, HSV 2, VZV), retroviruses, hepadnaviruses (e.g., HBV), papillomavirus, hantavirus, adenoviruses and HIV.
• herpesviruses e.g., CMV, HSV 1, HSV 2, VZV
• retroviruses e.g., hepadnaviruses
• hepadnaviruses e.g., HBV
• papillomavirus hantavirus
• adenoviruses adenoviruses
• HIV HIV.
• U.S. Patent No. 6,043,230 (incorporated by reference herein in its entirety) and other publications describe the antiviral specificity
• Tenofovir alafenamide is another prodrug form of tenofovir, and can be used in the treatment and/or prophylaxis of the same conditions.
• Tenofovir alafenamide hemifumarate can be administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including ocular, buccal, and sublingual), vaginal, and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural). Generally, tenofovir alafenamide hemifumarate is administered orally, but it can be administered by any of the other routes noted herein.
• compositions include those suitable for topical or systemic administration, including oral, rectal, nasal, buccal, sublingual, vaginal, or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural) administration.
• parenteral including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural administration.
• the formulations are in unit dosage form and are prepared by any of the methods well known in the art of pharmacy.
• the tenofovir alafenamide hemifumarate may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
• Such pharmaceutical compositions and preparations will typically contain at least 0.1% of tenofovir alafenamide hemifumarate.
• the percentage of this active compound in the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% or more of the weight of a given unit dosage form.
• the amount of active compound in such therapeutically useful pharmaceutical compositions is preferably such that an effective dosage level will be obtained upon administration of a single-unit dosage (e.g., tablet).
• Other dosage formulations may provide therapeutically effective amounts of tenofovir alafenamide hemifumarate upon repeated administration of subclinically effective amounts of the same.
• Preferred unit dosage formulations include those containing a daily dose (e.g., a single daily dose), as well as those containing a unit daily subclinical dose, or an appropriate fraction thereof (e.g., multiple daily doses), of tenofovir alafenamide
• compositions suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of tenofovir alafenamide hemifumarate; as a powder or granules; as a solution or a suspension in an aqueous liquid or a nonaqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
• Tenofovir alafenamide hemifumarate may also be presented as a bolus, electuary, or paste.
• Tenofovir alafenamide hemifumarate is preferably administered as part of a pharmaceutical composition or formulation.
• Such pharmaceutical composition or formulation comprises tenofovir alafenamide hemifumarate together with one or more pharmaceutically acceptable carriers / excipients, and optionally other therapeutic ingredients.
• the excipient(s) / carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the patient.
• Excipients include, but are not limited to, substances that can serve as a vehicle or medium for tenofovir alafenamide hemifumarate (e.g., a diluent carrier). They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
• the tablets, troches, pills, capsules, and the like may also contain, without limitation, the following: a binder(s), such as hydroxypropyl cellulose, povidone, or hydroxypropyl methylcellulose; a filler(s), such as microcrystalline cellulose, pregelatinized starch, starch, mannitol, or lactose monohydrate; a disintegrating agent(s), such as croscarmellose sodium, cross- linked povidone, or sodium starch glycolate; a lubricant(s), such as magnesium stearate, stearic acid, or other metallic stearates; a sweetening agent(s), such as sucrose, fructose, lactose, or aspartame; and/or a flavoring agent(s), such as peppermint, oil of wintergreen, or a cherry flavoring.
• a binder(s) such as hydroxypropyl cellulose, povidone, or hydroxypropyl methylcellulose
• the unit dosage form When the unit dosage form is a capsule, it may contain, in addition to materials of the above types, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, polymers, wax, shellac, or sugar and the like. Of course, any material used in preparing any unit dosage form typically will be pharmaceutically acceptable and substantially nontoxic in the amounts employed. In addition, tenofovir alafenamide hemifumarate may be incorporated into sustained-release preparations and devices.
• a liquid carrier such as a vegetable oil or a polyethylene glycol.
• Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, polymers, wax, shellac, or sugar and the like.
• any material used in preparing any unit dosage form typically will
• the pharmaceutical compositions are preferably applied as a topical ointment or cream containing tenofovir alafenamide hemifumarate in an amount of, for example, 0.01 to 10% w/w (including active ingredient in a range between 0.1% and 5% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 3% w/w and most preferably 0.5 to 2% w/w.
• the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
• the active ingredient may be formulated in a cream with an oil-in-water cream base.
• compositions suitable for topical administration in the mouth include lozenges comprising tenofovir alafenamide hemifumarate in a flavored basis, for example, sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
• Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
• compositions suitable for parenteral administration are sterile and include aqueous and nonaqueous injection solutions that may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and nonaqueous sterile suspensions that may include suspending agents and thickening agents.
• the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier (e.g., water for injections) immediately prior to use.
• the sterile liquid carrier e.g., water for injections
• Injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the kind previously described.
• the pharmaceutical compositions / formulations may include other ingredients conventional in the art, having regard to the type of formulation in question.
• veterinary compositions comprising tenofovir alafenamide hemifumarate together with a veterinary carrier therefor.
• Veterinary carriers are materials useful for the purpose of administering the composition to cats, dogs, horses, rabbits, and other animals, and may be solid, liquid, or gaseous materials that are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally, or by any other desired route.
• the tenofovir alafenamide hemifumarate can be used to provide controlled release pharmaceutical formulations containing a matrix or absorbent material and an active ingredient of the invention, in which the release of the active ingredient can be controlled and regulated to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the compound.
• Controlled release formulations adapted for oral administration in which discrete units comprising a compounds of the invention, can be prepared according to conventional methods.
• Useful dosages of tenofovir alafenamide hemifumarate can be determined by comparing in vitro activities, and the in vivo activities in animal models. Methods for the extrapolation of effective amounts / dosages in mice and other animals to therapeutically effective amounts / dosages in humans are known in the art.
• the amount of tenofovir alafenamide hemifumarate required for use in treatment will vary with several factors, including but not limited to the route of administration, the nature of the condition being treated, and the age and condition of the patient; ultimately, the amount administered will be at the discretion of the attendant physician or clinician.
• the therapeutically effective amount / dose of tenofovir alafenamide hemifumarate depends, at least, on the nature of the condition being treated, any toxicity or drug interaction issues, whether the compound is being used prophylactically (e.g., sometimes requiring lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies.
• the oral dose of tenofovir alafenamide hemifumarate may be in the range from about 0.0001 to about 100 mg/kg body weight per day, for example, from about 0.01 to about 10 mg/kg body weight per day, from about 0.01 to about 5 mg/kg body weight per day, from about 0.5 to about 50 mg/kg body weight per day, from about 1 to about 30 mg/kg body weight per day, from about 1.5 to about 10 mg/kg body weight per day, or from about 0.05 to about 0.5 mg/kg body weight per day.
• the daily candidate dose for an adult human of about 70 kg body weight will range from about 0.1 mg to about 1000 mg, or from about 1 mg to about 1000 mg, or from about 5 mg to about 500 mg, or from about 1 mg to about 150 mg, or from about 5 mg to about 150 mg, or from about 5 mg to about 100 mg, and may take the form of single or multiple doses.
• compositions described herein may further include one or more therapeutic agents in addition to tenofovir alafenamide
• the additional therapeutic agent can be selected from the group consisting of HIV protease inhibiting compounds, HIV nonnucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
• Therapeutic methods include administering tenofovir alafenamide hemifumarate to a subject / patient in need of the same as a therapeutic or preventative treatment.
• tenofovir alafenamide hemifumarate may be administered to a subject / patient having a medical disorder or to a subject who may acquire the disorder.
• Such treatment is given in order to ameliorate, prevent, delay, cure, and/or reduce the severity of a symptom or set of symptoms of a disorder (including a recurring disorder).
• the treatment may also be given to prolong the survival of a subject, e.g., beyond the survival time expected in the absence of such treatment.
• the medical disorders that may be treated with tenofovir alafenamide hemifumarate include those discussed herein, including without limitation, HIV infection and HBV infection.
• Example 1 The following are nonlimiting, illustrative Examples.
• Example 1 The following are nonlimiting, illustrative Examples.
• the solids were dried in a vacuum oven at 40 °C overnight. 5.52 g off-white solids were obtained. The solids were analyzed by XRPD and found to contain tenofovir alafenamide monofumarate, GS-7339 monofumarate, and tenofovir alafenamide hemifumarate.
• the mixture was cooled over a minimum of 4 hours to 0-6 °C, and then agitated at 0-6 °C for a minimum of 1 hour.
• the resulting slurry was filtered and rinsed with chilled (0-6 °C) ACN (2 kg).
• the product was dried under vacuum below 45 °C until loss on drying (LOD) and organic volatile impurities (OVI) limits were met (LOD ⁇ 1.0%, dichloromethane content ⁇ 0.19%, acetonitrile content ⁇ 0.19%) to afford the final compound of the hemifumarate form of tenofovir alafenamide as a white to off- white powder (typical yield is about 0.95 kg).
• Tenofovir alafenamide hemifumarate from Example 3 consists of 9-[(R)- 2-[[(S)-[[(S)-l-
• Tenofovir alafenamide hemifumarate is anhydrous, nonhygroscopic, and has a DSC onset endotherm of about 131 °C.
• the XRPD pattern for tenofovir alafenamide hemifumarate is shown in FIG. 1.
• the characteristic peaks include: 6.9 ⁇ 0.2°, 8.6 ⁇ 0.2°, 10.0 ⁇ 0.2°, 11.0 ⁇ 0.2°, 12.2 ⁇ 0.2°, 15.9 ⁇ 0.2°, 16.3 ⁇ 0.2°, 20.2 ⁇ 0.2°, and 20.8 ⁇ 0.2°.
• the crystal size was 0.32 x 0.30 x 0.20 mm 3 .
• the sample was held at 123 K and the data was collected using a radiation source with a wavelength of 0.71073 A in the theta range of 1.59 to 25.39°.
• Conditions of, and data collected from the single-crystal X-ray diffraction are shown in Table 1.
• the DSC analysis was conducted using 2.517 mg of tenofovir alafenamide hemifumarate. It was heated at 10 °C/min over the range of 40-200 °C. The onset endotherm was found to be about 131 °C (FIG. 2).
• TGA data were obtained using 4.161 mg of tenofovir alafenamide hemifumarate. It was heated at 10 °C/min over the range of 25-200 °C. The sample lost 0.3% weight before melting (FIG. 3). It was determined to be an anhydrous form.
• one of the major impurities is typically the diastereomer 9-[(R)-2-[[(R)-[[(S)-l- (isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine.
• the hemifumarate form of tenofovir alafenamide from Example 3 has an exceptional capability to purge this diastereomeric impurity, as compared with the capability of the monofumarate form (described in U.S. Patent
• Stable form screening of tenofovir alafenamide hemifumarate showed that it is thermodynamically stable in most solvents, such as ACN, toluene, ethyl acetate, methyl tert-butyl ether (MTBE), acetone, THF, and 2-methyl THF.
• solvents such as ACN, toluene, ethyl acetate, methyl tert-butyl ether (MTBE), acetone, THF, and 2-methyl THF.
• a similar stable form screening of the monofumarate form showed that this form is not thermodynamically stable in the above-listed solvents.
• the monofumarate form of tenofovir alafenamide When suspended in these solvents, the monofumarate form of tenofovir alafenamide fully converts to the hemifumarate form in THF and 2-methyl THF, and partially converts to the hemifumarate form in ACN, ethyl acetate, MTBE, and acetone, as well as at ambient temperatures.
• the hemifumarate form of tenofovir alafenamide has a melting point that is about 10 °C higher than that of the monofumarate form, indicating that the hemifumarate form has improved thermal stability as compared with the monofumarate form.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Molecular Biology (AREA)
• Virology (AREA)
• Epidemiology (AREA)
• Communicable Diseases (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Oncology (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Engineering & Computer Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Medicinal Preparation (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (35)

Applications Claiming Priority (2)

Publications (1)

Family

ID=46785793

Family Applications (1)

Country Status (41)

Cited By (26)

Families Citing this family (68)

Citations (2)

Family Cites Families (24)

• 2012
  • 2012-08-15 ES ES12753867T patent/ES2608871T5/es active Active
  • 2012-08-15 JP JP2014526164A patent/JP5651275B2/ja active Active
  • 2012-08-15 MX MX2014001549A patent/MX336627B/es unknown
  • 2012-08-15 CN CN201910647566.6A patent/CN110343135A/zh active Pending
  • 2012-08-15 WO PCT/US2012/050920 patent/WO2013025788A1/en not_active Ceased
  • 2012-08-15 SG SG2014011548A patent/SG2014011548A/en unknown
  • 2012-08-15 EP EP20206486.1A patent/EP3831832A1/en active Pending
  • 2012-08-15 CA CA2845553A patent/CA2845553C/en active Active
  • 2012-08-15 IN IN1012DEN2014 patent/IN2014DN01012A/en unknown
  • 2012-08-15 UY UY0001034262A patent/UY34262A/es active IP Right Grant
  • 2012-08-15 PE PE2014000206A patent/PE20141328A1/es active IP Right Grant
  • 2012-08-15 EP EP12753867.6A patent/EP2744810B2/en active Active
  • 2012-08-15 AU AU2012296622A patent/AU2012296622C1/en active Active
  • 2012-08-15 KR KR1020147003886A patent/KR101612642B1/ko active Active
  • 2012-08-15 DK DK12753867.6T patent/DK2744810T4/da active
  • 2012-08-15 CN CN201280039891.0A patent/CN103732594A/zh active Pending
  • 2012-08-15 LT LTEP12753867.6T patent/LT2744810T/lt unknown
  • 2012-08-15 BR BR112014003420-6A patent/BR112014003420B1/pt active IP Right Grant
  • 2012-08-15 US US13/586,358 patent/US8754065B2/en active Active
  • 2012-08-15 HU HUE12753867A patent/HUE031253T2/en unknown
  • 2012-08-15 MD MDA20140011A patent/MD4508C1/ro active IP Right Grant
  • 2012-08-15 TW TW101129542A patent/TWI516499B/zh active
  • 2012-08-15 AR ARP120102988A patent/AR087546A1/es not_active Application Discontinuation
  • 2012-08-15 SI SI201230807T patent/SI2744810T2/sl unknown
  • 2012-08-15 AP AP2014007437A patent/AP3639A/xx active
  • 2012-08-15 PT PT127538676T patent/PT2744810T/pt unknown
  • 2012-08-15 SM SM20160476T patent/SMT201600476T1/it unknown
  • 2012-08-15 PL PL12753867.6T patent/PL2744810T5/pl unknown
  • 2012-08-15 RS RS20161018A patent/RS55353B2/sr unknown
  • 2012-08-15 EA EA201490208A patent/EA027768B1/ru active Protection Beyond IP Right Term
  • 2012-08-15 UA UAA201401084A patent/UA115311C2/uk unknown
  • 2012-08-15 HR HRP20161696TT patent/HRP20161696T4/hr unknown
  • 2012-08-15 ME MEP-2016-273A patent/ME02612B/me unknown
  • 2012-08-15 EP EP16153076.1A patent/EP3070088A1/en not_active Withdrawn
  • 2012-08-15 PH PH1/2014/500349A patent/PH12014500349A1/en unknown
  • 2012-08-15 FI FIEP12753867.6T patent/FI2744810T4/fi active
• 2014
  • 2014-01-24 ZA ZA2014/00582A patent/ZA201400582B/en unknown
  • 2014-02-12 CO CO14029801A patent/CO6880063A2/es unknown
  • 2014-02-12 CR CR20140072A patent/CR20140072A/es unknown
  • 2014-02-12 MA MA36754A patent/MA35350B1/fr unknown
  • 2014-02-13 CL CL2014000370A patent/CL2014000370A1/es unknown
  • 2014-02-13 EC ECSP14013206 patent/ECSP14013206A/es unknown
  • 2014-02-13 IL IL230949A patent/IL230949A/en active IP Right Grant
  • 2014-03-05 US US14/197,873 patent/US9296769B2/en active Active
  • 2014-11-14 JP JP2014231819A patent/JP5956537B2/ja active Active
• 2015
  • 2015-08-18 IL IL240649A patent/IL240649A0/en unknown
• 2016
  • 2016-06-16 JP JP2016120153A patent/JP6280162B2/ja active Active
  • 2016-12-22 CY CY20161101331T patent/CY1118385T1/el unknown
  • 2016-12-28 SM SM201600476T patent/SMT201600476B/it unknown
• 2018
  • 2018-01-18 JP JP2018006107A patent/JP2018065870A/ja not_active Withdrawn
• 2019
  • 2019-11-21 JP JP2019210196A patent/JP2020040972A/ja active Pending

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events